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Abstract
Objective: Parkinson disease (PD) is defined by the accumulation of misfolded
a-synuclein (a-syn) in Lewy bodies and Lewy neurites. It affects multiple cortical and subcortical neuronal populations. The majority of people with PD
develop dementia, which is associated with Lewy bodies in neocortex and
referred to as Lewy body dementia (LBD). Other neuropathologic changes,
including amyloid b (Ab) and tau accumulation, occur in some LBD cases. We
sought to quantify a-syn, Ab, and tau accumulation in neocortical, limbic, and
basal ganglia regions. Methods: We isolated insoluble protein from fresh frozen
postmortem brain tissue samples for eight brains regions from 15 LBD, seven
Alzheimer disease (AD), and six control cases. We measured insoluble a-syn,
Ab, and tau with recently developed sandwich ELISAs. Results: We detected a
wide range of insoluble a-syn accumulation in LBD cases. The majority had
substantial a-syn accumulation in most regions, and dementia severity correlated with neocortical a-syn. However, three cases had low neocortical levels
that were indistinguishable from controls. Eight LBD cases had substantial Ab
accumulation, although the mean Ab level in LBD was lower than in AD. The
presence of Ab was associated with greater a-syn accumulation. Tau accumulation accompanied Ab in only one LBD case. Interpretation: LBD is associated
with insoluble a-syn accumulation in neocortical regions, but the relatively low
neocortical levels in some cases suggest that other changes contribute to
impaired function, such as loss of neocortical innervation from subcortical
regions. The correlation between Ab and a-syn accumulation suggests a pathophysiologic relationship between these two processes.

Introduction
The clinical diagnostic features of Parkinson disease (PD)
include a combination of tremor, bradykinesia, rigidity,
and impaired postural reflexes. PD is defined pathologically by brainstem catecholaminergic neuronal loss,
106

gliosis, and the accumulation of aggregated or misfolded
alpha-synuclein (a-syn) in neuronal cytoplasmic and neuritic inclusions known as Lewy bodies (LBs) and Lewy
neurites (LNs).1 The identification of dominant mutations
in the gene encoding a-syn (SNCA) in rare familial versions of PD supports the role of a-syn in the pathogenesis
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of PD.2–9 Dementia occurs frequently in PD. It may begin
at approximately the same time as motor symptoms
(often referred to as Dementia with Lewy bodies or DLB)
or up to 20 years after the onset of motor symptoms (PD
with dementia or PDD). The term Lewy body dementia
(LBD) encompasses this spectrum of clinical presentations. Immunohistochemistry studies demonstrate that
widespread deposition of a-syn in neocortex, a marker of
impaired cortical neuron function, accompanies
dementia.10–14
Other neurodegenerative changes occur with cognitive
impairment in PD. Ab plaques and tau-containing neurofibrillary tangles, neuritic plaques, and dystrophic neurites
accumulate to variable extents in cases of PD with
dementia.10–13,15–17 Although substantial neocortical Ab is
common, substantial neocortical tau deposition occurs
less often, with pathologic tau accumulation more frequently limited to the medial temporal lobe. Therefore,
the combination of Ab and tau deposition is often not
sufficiently extensive to meet NIA-Reagan criteria for
pathologically definite AD or to account independently
for dementia according to NIA-AA criteria.18,19 However,
the processes leading to Ab and tau accumulation likely
contribute to limbic and neocortical neuronal dysfunction
and therefore may impact cognition.
Cognitive impairment in PD affects multiple domains
including executive function, visuospatial function, and
memory.20–23 Hallucinations and delusions frequently
accompany dementia in PD.23,24 An additional characteristic feature of dementia in PD is fluctuations in attention
and excessive daytime sleepiness. Possible anatomic and
neurochemical correlates of these various cognitive phenotypes include (1) dysfunction in frontal-striatal circuits
and the dopaminergic system relating to executive function25,26; (2) medial temporal lobe and basal forebrain
cholinergic system dysfunction relating to memory27,28;
(3) superior parietal, temporal, and visual association cortex dysfunction relating to visuospatial function29–31; (4)
amygdala, hippocampus, parietal cortex, and occipital
cortex dysfunction relating to hallucinations and delusions32,33; and (5) serotonergic and noradrenergic projections, thalamus, and diffuse neocortex dysfunction
relating to fluctuating attention.32–35 To better understand
the pathologic substrates of dementia, we need to better
define the relationships between cognitive phenotypes and
the deposition of the various protein species in limbic
and neocortical regions.
Most previous studies of the neuropathology of PD
assessed the deposition of aggregated protein species with
immunohistochemistry (IHC). The patterns of protein
deposition are complex, encompassing a range of morphology and subcellular localization. In the case of a-syn,
IHC identifies a-syn accumulation in neuritic processes

(LNs) and presynaptic terminals (often referred to as
grains) in addition to neuronal cytoplasmic inclusions
(LBs). Ab accumulates in diffuse and cored plaques and
in blood vessel walls. Aggregated or misfolded tau accumulates in neurofibrillary tangles (NFTs) within neuronal
cytoplasm and proximal dendrites, dystrophic neurites of
neuritic plaques, and neuropil threads. Different patterns
of tau accumulation may reflect different pathologic processes and have different effects on brain function. IHC
has been quantified by image analysis, yielding estimates
of densities of pathologic protein deposition in different
brain regions.17,36,37 Alternatively, biochemical approaches
can quantify protein accumulation in frozen tissue
samples.
For this study, we developed new methods to quantify
the burden of insoluble protein accumulation in frozen
tissue samples from individual brain regions. We then
applied these methods to postmortem tissue samples collected from a pilot study of 15 clinically and neuropathologically well-characterized cases of LBD participants who
were in a longitudinal clinical study of PD. This enabled
our initial analysis of the relationships between misfolded
protein accumulation and dementia as well as relationships between the accumulation of different pathologic
protein species.

Subjects and Methods
Standard protocol approvals and patient
consents
The Human Research Protection Office at Washington
University in Saint Louis approved this study. Written
informed consent to perform a brain autopsy was
obtained from all participants. After death, the immediate
next-of-kin were contacted and confirmed consent for
brain removal and retention of brain tissue for research
purposes.

Study participants
The cohort included 15 PD participants with dementia,
seven AD participants, and six healthy age-matched neurologically normal control participants. All PD participants and one control participant (the first 16 to die in
this longitudinal study of PD and controls) were recruited
through the Movement Disorders Center (MDC) and five
control participants were recruited through the Knight
Alzheimer Disease Research Center (ADRC), as described
previously.38 Two AD participants were recruited through
the MDC and five AD participants were recruited from
the Knight ADRC. Both centers are located at Washington University in Saint Louis. The five controls from the
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ADRC and the seven AD participants were included posthumously based on clinical and neuropathologic features.
Postmortem brain tissue was collected between April 2008
and May 2016 and evaluated by IHC staining and neuropathological staging as previously described.39–48 Inclusion
criteria for the study were (1) PD participants who had a
clinical diagnosis of idiopathic PD based on the UK Parkinson Disease Society Brain Bank diagnostic criteria49
and either Clinical Dementia Rating (CDR global
score)50 ≥1 or a clinical diagnosis of dementia; (2) control
participants with CDR ≤ 0.5, Braak Stage 0 LB pathology,
Braak stage 0–B Ab pathology,41 and Braak stage I-III tau
pathology41; and (3) AD participants with CDR ≥1 or
clinical diagnosis of dementia, Braak stage C Ab pathology, Braak stage V–VI tau pathology.

Motor assessments
MDC clinicians evaluated motor symptoms using the
Unified Parkinson Disease Rating Scale motor subscale III
(UPDRS-III).51 Evaluations were performed OFF antiparkinsonian medications.

Dementia ratings
Dementia was rated using the CDR scale by experienced
raters. The CDR included an assessment of whether cognitive dysfunction was sufficiently severe to impair activities of daily living. PD participants were recruited into
the longitudinal study regardless of the presence of cognitive decline and regardless of the time of onset of cognitive decline or dementia (as elicited by history) relative to
the onset of motor symptoms. Prior to death, all PD participants had CDR ≥ 1, in accordance with criteria for
dementia in PD.23

Tissue Processing and Extraction
Frozen tissue was dissected from the right hemibrain.
Insoluble protein was isolated from frozen tissue samples
by sequential extraction and centrifugation. The insoluble
fraction was then solubilized in 2% SDS with heating and
sonication. Additional details are provided in the supporting information.

ELISA
All ELISAs used the following protocol unless otherwise
stated. Costar 96 well, clear, flat bottom, half area, high
binding, polystyrene plates (Corning #3690) were used.
The capture antibodies (Table S1) were diluted 1 lg/mL
in 34 mM sodium bicarbonate, 16 mM sodium carbonate
solution with 3 mM sodium azide. The capture antibody
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solution was added (50 lL/well) and incubated overnight
at 4°C. Plates were washed 5X with 150 lL 1XPBS +
0.05% Tween-20/well. Plates were blocked with 150 lL of
2% BSA (Sigma-Aldrich #A7906) in PBS at 37°C for 2 h.
Prior to standard and sample addition, plates were
washed as previously stated. Samples were diluted at
1:33.3 in sample buffer containing no SDS to reach an
SDS concentration of 0.06%. Standards and samples were
added to the plate 50 lL/well in duplicate wells and incubated overnight at 4°C with slow rotation. Plates were
washed as previously stated. The detection antibody
(Table S1) solution was diluted 1 lg/mL in PBS + 0.05%
BSA + 0.05% Tween. The detection antibody solution was
added 50 lL/well and incubated at 37°C for 2 hours.
Plates were washed as previously stated. Streptavidin
poly-HRP80 (Fitzgerald # 65R-S118) was diluted 1:8000
in 1% BSA in 1XPBS+0.05% Tween-20. The streptavidin
solution was added 50 lL/well and incubated for
90 minutes at room temperature in the dark. The plate
was washed as described previously. Fifty lL/well of
3,3’,5,5’-Tetramethylbenzidine Liquid Substrate, Super
Slow (Sigma # T5569) was rocked on the rotator until
first reading. Readings were done on Synergy 2 (BioTek)
at 650 nM at 9, 12, and 15 minutes. The time point with
the highest ratio between the top concentration and 0
concentration (background) in the standard curve was
chosen for data analysis.

Statistical analyses
Data were analyzed using GraphPad Prism software, version 8 (Graph Pad Software, Inc., La Jolla, CA). Due to
unequal group sizes and nonnormal distribution of data
points, nonparametric Mann–Whitney U tests were utilized to compare groups. Spearman correlation analysis
was used to analyze correlations between different protein
measures and between protein and cognitive function
measures. All tests were two-tailed and corrected for multiple comparisons with the Holm–Bonferroni method52
using a significance level of 0.05.

Results
Demographics and clinical information of
participants
Table 1 summarizes the demographics and clinical information of the study participants. Age at death did not
significantly differ between control and LBD participants.
The AD participants were younger at age of death. The
male/female ratio was higher in LBD compared with controls and AD. To analyze insoluble protein accumulation
in frozen postmortem tissue samples, we isolated
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insoluble protein by sequential extraction and centrifugation and then solubilized insoluble protein in 2% SDS.
We analyzed samples from eight brain regions: middle
frontal gyrus (MFG), anterior cingulate gyrus (ACG),
caudate, inferior parietal lobule (IPL), visual association
cortex (VAC), precuneus, hippocampus, and amygdala.

Assay performance characteristics of the
ELISA assays
We developed and validated sandwich ELISAs for a-syn,
p-a-syn, Ab(1-42), p-tau, and tau. Table S1 indicates
ELISA antibodies used for a-syn, p-a-syn, Ab, tau, and ptau. Representative standard curves for each ELISA are
shown in Fig. S1. The ELISA lower limit of quantification
(LLQ) for a-syn (Syn1/13G5B), p-a-syn, Ab, p-tau, and
tau were 0.15, 0.15, 0.014,17.5, and 0.125 ng/mL, respectively, which corresponded to 0.05, 0.01, 0.94, 1.75, and
0.33 µg/g wet weight tissue when adjusted for the sample
dilution used in each ELISA. Since all group comparisons
were performed for an individual brain region within the
same plate, the coefficients of variation (%CV) for four
intraplate controls were the most relevant measures of
assay consistency, which are included in Table S2.
Table 1. Demographic and clinical information of the autopsied
cases.

Demographics
Participants, N
Age at Death, y
Male/Female, N
Clinical characteristics
of LBD participants
Age at LBD diagnosis, y
Duration of motor
impairment, y
UPDRS-III score
(OFF medications)
LEDD, mg
SSRI medications, N
Other antidepressant
medications, Na
AChE inhibitor
medications, Nb
Neuroleptic
medications, Nc

LBD

Control

AD

15
81 (71-93)
12/3

6
84 (70-100)
2/4

7
73 (62-78)
4/3

63 (54–82)
14 (8–27)

NA
NA

NA
NA

44 (35–73.5)

NA

NA

800 (0–1350)
10/15
2/15

NA
NA
NA

NA
NA
NA

8/15

NA

NA

14/15

NA

NA

Abbreviations: AChE, acetylcholinesterase. Values are median (range)
unless otherwise indicated; LEDD, levodopa equivalent daily dose; NA,
not applicable; SSRI, selective serotonin reuptake inhibitors; UPDRS,
Unified Parkinson Disease Rating Scale; Y, years.
a
Mirtazapine and venlafaxine.
b
Donepezil, rivastigmine, and galantamine.
c
Quetiapine and clozapine.

Alpha-synuclein and phospho-alphasynuclein
We used our recently developed a-syn ELISA (Syn1/
13G5B)53 to measure insoluble a-syn in LBD, AD, and
control samples. The LBD cases had a wide range of asyn levels. Three LBD cases had a-syn levels that were
within the range of control cases for MFG, IPL, and
Prec, and an additional seven LBD cases overlapped with
control cases for IPL, and Prec (Fig. 1A and B). The
highest median levels of a-syn deposition in LBD cases
were found in MFG, caudate, and amygdala, whereas,
the VAC had very little a-syn in all LBD cases. We consistently observed quantifiable a-syn levels in control
cases, which may represent a low level of aggregated asyn in brain tissue from older controls, or alternatively,
it may represent a carryover of the highly abundant soluble a-syn fraction during the preparation of insoluble
fractions.
Since immunohistochemistry produces highly selective
staining for pathologic a-syn when phospho-serine 129 asyn antibodies are utilized, we also developed an ELISA
utilizing the anti-phospho-serine 129 a-syn antibody
psyn81a. p-a-syn was below LLQ in all Control brain
samples with the exception of one MFG and one ACG
sample (Fig. 2). Consistent with the a-syn measurements,
p-a-syn levels in LBD were below the LLQ in MFG for
three cases and were below LLQ in IPL for seven cases
and precuneus for six cases (Fig. 2A). The highest median
levels of p-a-syn accumulation were found in ACG, caudate, and amygdala. Levels were below the LLQ in all but
two LBD cases for VAC. a-syn and p-a-syn were significantly correlated in all regions, but correlations were
much stronger in regions such as caudate, hippocampus,
and amygdala compared with other regions with weaker
correlations such as ACG, MFG, and IPL (Fig. 3). We did
not observe detectable p-a-syn deposition in samples
from AD cases (Fig. 2B).
We also analyzed the LBD cases but not Control or AD
cases with our previously published a-syn ELISA that uses
Syn211 and FL140 antibodies (Fig. S2). This ELISA is significantly less sensitive than the Syn1/13G5 ELISA and is
also not available for continued use because the polyclonal FL140 antibody has been discontinued by the commercial supplier. We analyzed correlations between the
two a-syn ELISAs and observed significant correlations in
all brain regions except ACG (Fig. S3). The highest
median levels of a-syn measured by the Syn211/FL140
ELISA were in ACG, caudate, hippocampus, and amygdala. There was a significant correlation between a-syn
Syn211/FL140 ELISA and p-a-syn in all brain regions
(Fig. S4). The strongest correlations were found in MFG,
caudate, and precuneus.
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α-syn (μg/g. wet wt.)
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Figure 1. Regional distribution of insoluble a-syn concentration in LBD and Control cases (Syn1-13G5B ELISA). Levels of insoluble a-syn were
measured by sandwich ELISA in eight brain regions from LBD (black circles) cases (A) and four brain regions from control (red triangles) and AD
(blue diamonds) cases (B). There was a wide range of a-syn accumulation among LBD cases, including some cases in which a-syn accumulation
overlapped with levels measured in control cases. The highest median levels of a-syn deposition were in MFG, caudate, and amygdala. Control
and AD cases had low levels of insoluble a-syn in all brain regions tested. The lower limit of quantification (LLQ) for the ELISA was 0.15 ng/mL or
0.05 µg/g wet wt tissue. All samples were in the quantifiable range. The a-syn level in MFG was significantly higher in LBD compared with
control cases. Data were analyzed with the two-tailed Mann–Whitney test using a significance level of 0.05 and corrected for multiple
comparisons with the Holm-Bonferroni method.52 Mid-Frontal Gyrus (MFG), Anterior Cingulate Gyrus (ACG), Caudate (Cau), Inferior Parietal
Lobule (IPL), Visual Association cortex (VAC), Precuneus (Prec), Hippocampus (Hip), and Amygdala (Amy).

Ab(1-42)
Accumulation of Ab is a hallmark of AD and has also
been implicated in the development of dementia in LBD
patients.10,12,41,42,45,54–57 We used a well-characterized
ELISA that is selective for Ab(1-42), the predominant Ab
species in plaques.58 We detected insoluble Ab(1-42), in 8
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of the 15 (53%) LBD cases studied (Fig. 4A), and these
LBD cases had widespread Ab accumulation by IHC
(Table S3). The highest levels by ELISA of Ab for LBD
were found in MFG, ACG, and IPL. These eight LBD
cases with quantifiable Ab levels were compared with AD
cases (Fig. 4B), and the mean level of Ab was lower in
LBD cases compared with AD cases in all four regions.
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Figure 2. Regional distribution of p-a-syn concentration in LBD and Control cases (pSyn/81A-Syn1B ELISA). Levels of insoluble p-a-syn were
measured by sandwich ELISA in eight brain regions from LBD (black circles) cases (A) and four brain regions from control (red triangles) and AD
(blue diamonds) cases (B). The highest median levels of p-a-syn in LBD cases were in ACG, caudate, and amygdala. The LLQ for the ELISAs was
0.15 ng/mL or 9.99 ng/g wet wt tissue. All samples from control and AD cases were below the lower limit of quantification for p-a-syn except
one control MFG sample and one control ACG sample. The a-syn level in ACG was significantly higher in LBD compared with control cases. Data
were analyzed with the two-tailed Mann–Whitney test using a significance level of 0.05 and corrected for multiple comparisons with the HolmBonferroni method.52

Levels in LBD and AD were compared using the Mann–
Whitney test and corrected for multiple comparisons with
the Holm-Bonferroni method. Two control cases had elevated levels of Ab, one with substantially elevated levels
in all four brain regions analyzed (Fig. 4B). Both these
control cases had Braak stage B Ab pathology by IHC.
Previous histologic studies observed correlations
between LB and Ab plaque density in LBD. We compared
insoluble a-syn in subgroups defined by the presence or
absence of Ab accumulation. The LBD with Ab

accumulation subgroup had significantly higher a-syn
levels in ACG and amygdala (Fig. 5). In addition, there
was a consistent trend toward higher mean a-syn levels in
the subgroup with Ab accumulation for all regions. Similar results were observed for the comparison of p-a-syn
levels between the two subgroups (Fig. S6). We also
analyzed correlations between insoluble a-syn and Ab
measured by the ELISAs. Significant correlations between
a-syn (Syn1/13G5B ELISA) and Ab in LBD cases were
found in ACG, IPL, precuneus, and amygdala (Fig. 6).
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Figure 3. Correlations between insoluble a-syn (Syn1-13G5B ELISA) and p-a-syn (pSyn/81A-Syn1B ELISA) concentration measurements in LBD
cases. We observed significant correlations (Spearman) between a-syn and p-a-syn in all eight brain regions: (A) MFG, (B) ACG, (C) caudate, (D)
IPL, (E) VAC, (F) precuneus, (G) hippocampus, (H) amygdala, with the strongest correlations (Spearman rho values > 0.9) in caudate,
hippocampus, and amygdala. Data were corrected for multiple comparisons with the Holm-Bonferroni method.52 Lines were generated by linear
regression.

We found correlations between Ab and a-syn measured
by syn211/FL140 ELISA (Fig. S5) in four of the eight
brains regions (amygdala, precuneus, MFG, and IPL).
Three of the four brains regions with significant correlations (IPL, precuneus, and amygdala) were common
between the two a-syn ELISAs. Three brain regions
(MFG, amygdala, and precuneus) had significant correlations between p-a-syn and Ab (Fig. S7).

Tau and phospho-tau
Tauopathy is strongly associated with the development of
dementia in AD.39,41,59 Immunohistochemistry studies
have identified hyperphosphorylated tau accumulation in
LBD cases. 10,11,17,37,54,57,60 We utilized an ELISA to measure total insoluble tau and also developed an ELISA for
p-tau based on the PHF-1 antibody. PHF-1 is specific for
tau phosphorylation at serine 396/404 and is commonly
used for histolopathologic analysis of tau accumulation.
One LBD case had elevated p-tau accumulation relative
to other LBD cases in all regions, although it was still
within the range of the levels found in Control cases and
lower than most AD cases (Fig. 7A and B). This case also
had increased deposition of total tau relative to the other
LBD cases (Fig. S8A). AD cases had elevated levels of tau
compared with LBD cases (Fig. S8B). We observed tau
and p-tau correlations in caudate and VAC, but not in
other regions for LBD cases (Fig. S9). We detected a
significant correlation between total tau and a-syn
(Syn1-13G5B) in VAC and amygdala and detected a
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correlation between total tau and Ab in MFG, but we did
not identify significant correlations between p-tau and
either a-syn or Ab in LBD cases (data not shown).

Histology vs ELISA
We used immunohistochemistry to analyze formalin-fixed
paraffin-embedded tissue samples from the contralateral
(left) hemibrain of each LBD case, according to our diagnostic neuropathology protocols.43 Six of the eight brain
regions analyzed by ELISA also were scored for pathologic
burden of LBs identified by p-a-syn staining; diffuse plaques (DP) and cored plaques (CP) identified by Ab staining; and NFTs and neuritic plaques (NP) identified by
p-tau staining. We compared histopathology scores to the
ELISA results for p-a-syn, Ab, and p-tau (Fig. S10-S11).
We performed an exploratory Spearman correlation analysis, which was limited by the poor distribution of data
points for most analyses. DP and CP scores correlated to
some degree with ELISA measures of Ab for most
regions, but there was no indication of correlations
between LB scores and ELISA measures or between NFT
or NP scores and ELISA measures.

Dementia severity vs ELISA
Since all the LBD cases were diagnosed with dementia, we
compared the CDR sum of boxes score and MMSE scores
closest to the time of death with the mean level of p-asyn detected in the neocortical regions of MFG, IPL,
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Figure 4. Regional distribution of insoluble Ab(1-42) concentration in LBD, Control, and AD cases. Levels of insoluble Ab(1-42) were measured by
sandwich ELISA. (A) Eight of the 15 cases had measurable Ab levels in most brain regions. For LBD cases with measurable Ab, the highest levels
of Ab were found in MFG, ACG, IPL, and Precuneus. (B) Ab levels were measurable in two of the six control (red triangles) cases. One control
case had high levels of Ab in all brain regions. AD (blue diamonds) cases had significantly higher Ab levels compared with the subgroup of LBD
(black circles) cases that had detectable Ab levels in all four brain regions examined. The LLQ for the ELISAs was 14.17 pg/mL or 0.63 µg/g wet
wt tissue. Data were analyzed with the two-tailed Mann–Whitney test using a significance level of 0.05 and corrected for multiple comparisons
with the Holm-Bonferroni method.52

VAC, and precuneus (Fig. 8). Dementia severity as measured by CDR sum of boxes correlated with higher p-asyn concentration. There was also a significant correlation
between worse MMSE and higher p-a-syn concentration.
There were no correlations between these cognitive measures and either mean neocortical insoluble Ab or mean
insoluble p-a-syn concentration in limbic regions (data
not shown). There were also no significant correlations
when we analyzed for correlations between each protein

measure and time from PD onset to dementia onset, age
of dementia onset, dementia duration, age at death, and
sex (data not shown).

Discussion
We report the results of a new approach to analyze the
accumulation of insoluble a-syn, Ab, and tau in Lewy
body dementia. Our approach relies on the isolation of
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Figure 5. Comparison of insoluble a-syn concentrations (Syn1-13G5B) between LBD with measurable Ab and LBD cases without measurable Ab.
The subgroup with Ab accumulation had significantly higher a-syn concentrations in ACG and amygdala, compared with the subgroup without
measurable Ab. Mean a-syn levels were 18% higher in the PD with Ab accumulation subgroup in the hippocampus and were 32%–73% in other
regions. Data were analyzed with the two-tailed Mann–Whitney test using a significance level of 0.05 and corrected for multiple comparisons
with the Holm-Bonferroni method.52
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Figure 6. Correlations between a-syn (Syn1-13G5B ELISA) and Ab concentrations in LBD cases. We observed significant correlations (Spearman)
between a-syn and Ab in four (ACG (B), IPL (D), precuneus (F), and amygdala (H)) of the eight brain regions. Data were corrected for multiple
comparisons with the Holm-Bonferroni method.52 Lines were generated by linear regression.

insoluble protein from frozen postmortem tissue, followed by solubilization in SDS and quantification by
sandwich ELISAs. We applied these methods to 15 cases
of LBD, measuring pathologic accumulation of a-syn,
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Ab42 and tau in eight brain areas; we also applied them
to seven AD cases and six controls, in four of these brain
areas. While all LBD cases had Braak stage 6 LB pathology as determined by standard immunohistochemistry
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Figure 7. Regional distribution of phospho-tau concentration in LBD, Control, and AD cases. Levels of insoluble phospho-tau were measured by
sandwich ELISA in eight brain regions from LBD cases (A), four brain regions from control (red triangles) cases, and four regions from AD cases
(blue diamonds) (B). The LBD cases (black circles) had low levels of p-tau. One LBD case had elevated p-tau accumulation relative to other LBD
cases in all regions, although it was still within the range of the levels found in control cases. The LBD cases were significantly lower than the
control and AD cases. The highest levels of p-tau in LBD cases were found in the caudate, hippocampus, and amygdala. The LLQ for the ELISAs
was 17.5 ng/mL or 1.75 µg/g wet weight tissue. Data were analyzed with the two-tailed Mann–Whitney test using a significance level of 0.05
and corrected for multiple comparisons with the Holm-Bonferroni method.52

analysis, we observed a wide range of insoluble a-syn
levels in basal ganglia, limbic and cortical regions, with a
subset of cases having low neocortical levels that were not
clearly distinguished from controls. Ab accumulated in
53% of the LBD cases, in line with previous immunohistochemistry studies. The LBD plus Ab subgroup had
higher a-syn accumulation compared with the LBD only
group in the majority of brain regions examined, and
levels of Ab correlated with levels of a-syn. However, in

contrast to the pathologic picture of symptomatic AD,
widespread pathologic Ab accumulation in LBD was not
accompanied by widespread tau accumulation. These
results provide new insight into pathophysiologic processes in PD, including the relationship between regional
a-syn accumulation and dementia as well as relationships
between different accumulating protein species.
The wide range of insoluble a-syn levels measured in
cortical, limbic, and basal ganglia regions indicates that
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Figure 8. Correlations between cognitive measures (CDR sum of boxes and MMSE) and neo-cortical phospho-alpha-synuclein levels in LBD cases.
We analyzed correlations (Spearman) between cognitive measures (CDR sum of boxes, MMSE) and total aggregated p-a-syn in the neocortical
regions of MFG, IPL, VAC, and precuneus. (A) There was a significant correlation between CDR sum of boxes score and neocortical p-a-syn
(p = 0.046, rho = 0.57). (B) There was also a significant negative correlation between MMSE and neocortical p-a-syn (p = 0.025; rho = 0.60).
Lines were generated by linear regression.

complex causes of brain dysfunction, beyond the level of
a-syn accumulation alone, underlie the cognitive impairment and dementia in LBD. Most consistent among the
15 cases is the high a-syn and p-a-syn accumulation in
ACG, caudate, amygdala, and hippocampus. In neocortical regions, many cases had high levels of insoluble a-syn.
However, three cases had low cortical a-syn concentrations that were not clearly distinguished from levels measured in control cases. Multiple studies have observed
that neocortical LBs are associated with dementia in
PD10–13 and these cases all had LBs in neocortical regions
that were sufficient to meet Braak stage 6 neuropathologic
criteria. However, for a subset of cases, the total burden
of a-syn fibrils present in a combination of LBs, LNs, and
grain pathology is relatively low and difficult to distinguish from Control cases. It is not clear whether the low
level of insoluble a-syn measured by our a-syn ELISA in
Control cases corresponds to the presence of a-syn fibrils.
It may instead represent the carryover of a small fraction
of soluble a-syn during multiple rounds of homogenization and centrifugation. Our p-a-syn ELISA appears to be
more specific for pathologic a-syn accumulation in LBD
cases since p-a-syn levels were not quantifiable in all but
two control tissue samples.
The mean neocortical p-a-syn concentration correlated
with dementia severity, as measured by CDR sum of
boxes score and MMSE. However, the wide range of
insoluble a-syn burden in neocortical regions, including a
subset of cases with low levels, indicates that changes
other than cortical neuron synucleinopathy may
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contribute to cognitive impairment in at least some cases.
Our observations overlap with other studies in which a
subset of LBD cases, classified as limbic or transitional
Lewy body disease,37,45,61 have high LB density in the
brainstem and limbic regions but low or absent LB
pathology in neocortical regions. We observe consistently
high levels of a-syn accumulation in the hippocampus,
amygdala, and caudate regions in LBD cases. We also previously reported the substantial loss of dopaminergic,
serotonergic, and noradrenergic innervation in neocortical, limbic, and basal ganglia regions for these same 15
LBD cases.38 Specifically, cases that had a low a-syn burden in this study had substantial deficits in dopaminergic,
serotonergic, and noradrenergic innervation of neocortical, limbic, and basal ganglia regions. These findings support the idea that loss of projections from subcortical
nuclei, including substantia nigra, raphe nuclei, and locus
coeruleus, also may contribute to the development of
dementia in LBD. Further studies of both pathologic protein accumulation and neurotransmitter deficits in additional cases, including cases without dementia, will help
to better define the relative contributions of these different pathologic substrates of dementia. Furthermore, analysis of additional cases may also reveal relationships to
deficits in specific cognitive domains.
The correlation between insoluble a-syn and Ab accumulation in LBD indicates a pathophysiologic relationship
that has implications for previously observed associations
of Ab with shorter survival13 and increased rate of cognitive decline in LBD.10,62,63 Previous studies have observed
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a-syn–Ab correlations based on immunohistochemistry
analysis of LBs and plaques.10,17,37,64,65 In PD, where CSF
levels of a-syn are lower compared with control cases,
levels of CSF a-syn and CSF Ab1-42 are correlated.66 These
correlations may arise from pathophysiologic mechanisms, such as impaired protein homeostasis, where
impaired protein turnover pathways affect both proteins.
Alternatively, metabolism changes, neuroinflammation, or
impaired synaptic function in PD may contribute to both
a-syn and Ab accumulation. We previously observed
shorter survival in LBD cases with Ab compared with
those without Ab accumulation.13 Others have observed
shorter time to develop cognitive impairment associated
with low CSF Ab levels.10,62,63 While these observations
may be explained by effects of Ab independent of a-syn,
the faster rate of disease progression may also relate to
increased a-syn deposition associated with Ab accumulation or the underlying disease mechanisms driving the
accumulation of both proteins.
We did not see substantial levels of insoluble phosphotau in the LBD cases with Ab accumulation. Only a single
LBD case overlapped with the range of phospho-tau levels
quantified in AD cases with Braak stage V and VI tau
pathology. This observation, which is similar to our previous observation that widespread tau deposition is rare
in PD based on immunohistochemistry analysis, indicates
that Ab accumulation is associated with distinct pathophysiologic processes in LBD. Tau accumulation, or pathways leading to tau accumulation, may be less involved in
LBD or at least less involved in neocortical regions compared with symptomatic AD. Other studies have observed
an association between Ab and tau accumulation based
on IHC scores and staging,10,17 and although tau accumulation is limited primarily to temporal lobe regions in
most cases, it may still contribute to cognitive dysfunction in PD.17,60 It is also possible that differences in the
patterns of pathologic protein deposition among different
centers may reflect differences in case selection; for example, individuals with a-syn accumulation only may be
more likely to present to movement disorder centers, and
those with co-occurring AD neuropathic changes may be
more likely to present to centers focusing on cognitive
disorders.10,11,17,37,54,57,60
The development of an a-syn PET imaging agent
would provide more detailed information on longitudinal
patterns of a-syn accumulation and their relationship to
clinical features of disease progression.67 One limitation
in interpreting our postmortem analysis is that we do not
know whether cell death late in the disease course may
lead to clearance of pathologic protein and a decline in
levels measured at autopsy, a question that can be
addressed by longitudinal PET studies. However, our
autopsy results provide guidance for the initial clinical

development of a-syn imaging agents. The a-syn ELISA
results highlight ACG, caudate, amygdala, and hippocampus as having the highest levels of a-syn accumulation in
LBD at autopsy among the brain areas sampled here.
Some, but not all, cases have high neocortical levels of asyn. IHC studies also endorse brainstem nuclei, olfactory
bulb, basal forebrain, and olfactory cortex as sites of
dense a-syn accumulation. The generally high variance in
a-syn accumulation among LBD cases predicts that variable signal will be observed among individuals in initial
clinical studies of a-syn PET tracers for PD and LBD.
Further ELISA analyses of PD cases without dementia,
which are less common at autopsy, will provide more
information about expected levels across the disease
spectrum.
Our study has several limitations with respect to the
goal of understanding relationships between insoluble
protein accumulation and clinical features of LBD. Our
sandwich ELISA approach improves throughput and precision for quantifying insoluble protein accumulation, but
throughput is still limited by the time required to dissect
and process frozen tissue samples. Quantification by the
ELISA method is applied to a relatively small sample of
frozen tissue. For quantification of caudate, ACG, and
neocortical regions, the values represent concentrations
present in approximately 1 g samples of gray matter,
whereas for hippocampus and amygdala, quantification is
based on 0.1 g samples, which are selected from cryostat
sections produced from brain regions where smaller volumes are available for analysis. The approach is not easily
applied to small subcortical nuclei, such as nucleus basalis, raphe nuclei, and locus coeruleus, where the tissue
volumes are very small, and regions of interest are more
difficult to isolate from frozen tissue. Because the analysis
relies on the isolation of an insoluble fraction, the burden
of soluble oligomeric species is not assessed. However,
our recent study using a similar biochemical fractionation
method indicates that levels of soluble oligomeric a-syn
species are very low, relative to insoluble a-syn, in PD tissue.68 The choice of antibodies for sandwich ELISAs may
bias toward detection of specific conformations and posttranslational modifications recognized with the highest
affinity by these antibodies. We utilized phosphorylationspecific antibodies to complement the analysis of “total”
a-syn and tau, which may improve specificity given the
preferential phosphorylation of insoluble species. However, antibodies used to measure total a-syn and tau also
may have biases toward specific species, which may
explain the imperfect correlations we observe between
sandwich ELISA values obtained with different a-syn
antibodies.
Additional studies are needed to better understand the
relationship between pathologic protein accumulation and
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dementia, including specific cognitive phenotypes associated with PD. The inclusion of cases without dementia
will be particularly helpful for future studies, which is
challenging given the relatively low number of cases at
autopsy. Analysis of additional markers, including
markers to identify the loss of innervation from subcortical nuclei, as well as the loss of cortical neurons, and their
connections, may also be helpful to understand the relative contributions of these pathologic changes and their
relationship to pathologic protein accumulation.
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Figure S2. Regional distribution of insoluble a-syn concentrations in LBD cases as measured by the Syn211FL140 ELISA.
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immunohistochemistry.
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ELISA assays.
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